

May 28, 2018

Dept. of Corporate Services Corporate Relationship Department BSE Ltd PhirozeJeejeebhai Towers, Dalal Street, Mumbai – 400001

Dear Sirs,

Sub:Outcome of the Board Meeting held on 28th May 2018Ref:1) Regulation 33 of SEBI (LODR) Regulations 20152) Scrip Code: 526783

The Board of directors of the company at its meeting held today:

- Approved and have taken on record the Audited Financial Results for the quarter and financial year ended 31<sup>st</sup> March 2018. In this regard, please find enclosed copies of the following:
  - i. Statement showing the Audited Financial Results for the quarter and financial year ended 31<sup>st</sup> March 2018.
  - ii. Auditors' Report on the said Financial Results.
  - iii. Declaration in respect of the Auditors' Report with Unmodified Opinion
- 2. The Board of Directors have recommended a dividend of 12% on the paid up equity share capital subject to approval of the shareholders at the ensuing Annual General Meeting.
- 3. The Company has also made arrangements for release of the Audited Results in the newspapers as per the requirement of the SEBI (LODR) regulations 2015.
- 4. Approved and took on record the resignation of Mr.R. Sabesan, Chief Financial Officer of the Company with effect from 31<sup>st</sup> March 2018.

Kindly take the above information on record.

Thanking you,

Yours sincerely,

DR. AMAR AGARWAL CHAIRMAN AND MANAGING DIRECTOR

#### **Registered** Office

3<sup>rd</sup> Floor, Buhari Towers, No.4, Moores Road, Off Greams Road, Near Asan Memorial School, Chennai - 600 006. Tel: 91-44-3991 6600 Fax: 91-44-3991 6645 Corporate ID Number: L85110TN1994PLC027366 GST No. 33AAACD2373G1Z2 Email: dragarwal@vsnl.com | Website: www.dragarwal.com



	Dr. Agarwal's Eye Hospital Limited Dr. Agarwal's Eye Hospital Limited CIN : L85110TN1994PLC027366 Regd Office: 3rd Floor, Buhari Towers, Nov, Moores Road, Off Greams Road, Chennai - 600 006 Phone No. 91-44-39016669 Mohstie - www.dranaral.com, Childrenand.com	Dr. Agarwal's Eye Hospital Limited CIN : L85110TN1994PLC027366 Towers: No.4, Mores Road, Pff of Proteire - wowd fragestrual CM of	lited 66 67 Greams Road, Cher 7 marit - Inværencente	mai - 600 006		
		5				(Amount in Rs. Lakhs)
	Statement of Audited Financial Results for the Year Ended 31 March 2018	al Results for the Yea	r Ended 31 March 201	8		
S.No.	Particulars	31-Mar-18 (Refer Note 3)	31-Dec-17 Unaudited	31-Mar-17 (Refer Note 3)	31-Mar-18 Audited	Tear Ended 31-Mar-17 Audited
-	Incorne Revenue from Operations	3,757.96		3,670,28		14
	(v) Cuter income Total Income	3,824.41	3,556.14	3,685,67	230.00 15,562.13	15,019.54
7	Expenses (a) Purchase of Stock-in-Trade (b) Changes in Inventories of Stock-in-Trade - (Increase) / Decrease	523.43 (19.84)	319.81 98.91	253.66 (10.63)	1,896.47 (81.82)	1,751.75 72.52
	(d) Consumations (d) Consultancy Charges (e) Employed Benefit Expenses	397.84 512.13 741.26	392.61 518.00 885.22	314.31 510.87 722.87	1,541.74 2,002.75 3 198 03	1,683.14 1,935.34 3 249 33
	(f) Finance Costs (c) Demectation and Amortisation Evence	95.50	57.59	75.53	259.04	333,30
	(h) For production and structure and the second structure (h) Chine Expenses	718.26 718.26	209.34 437.89 780.86	2/2.46 424.48 610.76	9/8.78 1.717.98 2.713.67	8/4.18 1,644.09 2,378.41
	Total Expenses	3,650.84	3,760.43	3,174.31	14,226.04	13,922.06
8	Profit / (Loss) before Exceptional items and Tax (1-2)	173.57	(204.29)	511.36	1,336.09	1,097.48
4	Exceptional items		,	,		
5	Profit / (Loss) before Tax (3-4)	173.57	(204.29)	511.36	1,336.09	1,097.48
Q	Tax Expense - Current Tax (including prior years) - Deferred Tax	146.55 110.41	(26.50) (44.98)	208,46 (40.38)	844.35 14.22	460.00 (96.35)
7	Net Profit / (Loss) after tax for the period (5-6)	(83.39)	(132.81)	343.28	677.52	733.83
æ	Other Comprehensive Income (a) Items that will not be reclassified to the Statement of Profit and Loss - Actuarial (orss) / gain on defined benefit obligation - Deforred Tax on Adjustments (b) Items that will be relassified to the Statement of Profit and Loss Total Other Comprehensive Income / (Loss) (net of tax)	(13.32) 2.51 	(8.26) 2.86 - (5.40)	(40.87) 14.14 - (26.73)	(38.19) 11.12 27.07)	(40.75) 14.10 (26.65)
თ	Total Comprehensive Income / (Loss) (7+8)	(94.20)	(138.21)	316.55	650.45	707.18
11 10	Pald-up equity share capital (Face value Rs, 10/ each) Reserves (Other Equity) Earlingto Ber Equity)	470.00	470.00	470.00	470.00 3,035.91	470.00 2470.31
	(a) Basic (b) Diluted	(1.77) (1.77) (not Annualised)	(2.83) (2.83) (not Annualised)	7.30 7.30 (not Annualised)	14.42 14.42 (Annualised)	15.61 15.61 (Annualised)

\* STANT SNINS \* DEFO!

A A ASSETS A ASSETS (9) Pro-eur (9) Ort (1) Car (1) Ca	Regd Office: 3rd Floor, Buhari Phone No. 9144-39916669 W Phone No. 9144-39916669 W Particulars BALANCE SHE Particulars Particu	Dr. Agarwal's Eye Hospital Limited CIN : L85110TN1994PLC027366 Towers, No.4, Moores Road, Off Gr febsite : www.dragarwal.com E-ma internet and the state internet and the state interne	ed Greams Road, Chenn mail : investor@drag As at 31-Mar-17 As at 33.97 33.97 33.97 33.97 833.81 833.81	ari - 600 006 arwal.com 01.Apr-15 7.6.20 7.23 7.390.62 7.3946 7.3946 7.3946 7.3946 7.3946 7.3946 7.3946 7.3946 7.3946 7.3946 7.3346 7.3355 5.243.59	(Amount in Rs. Lakhs)
	Particulars ss (ret) tis	31-Mar-18 Audited	As at 31-Mar-17 31-Mar-17 32.82.07 121.63 38.97 833.81 833.81 833.81	01-Apr-15 01-Apr-15 3,390 62 76.20 12.33 739.46 739.46 739.46 739.46 739.46 739.46 739.46 739.46	(Amount in Rs. Lakhs
	Particulars sigment (net) tis	31-Mar-18 Audited	As at 31-Mar-17 31-Mar-17 31-Mar-17 121 63 38.97 38.97 38.97 833.81 833.81 833.81	01-Apr-15 Audited 75.20 12.33 759.46 739.46 44.93 549.62 649.63 543.63	
Cu To Real	Particulars ss (net) tis	31-Mar-18 Audited	31-481-17 31-481-17 Audited 3.282.07 121.63 38.97 833.81 833.81 833.81 833.81	01-Apr-15 Audited 3,399 62 76.20 12.33 739.46 434.93 543.53 5,243.59	
Cr 10 No	IS rirrent assets rippenty, plant and equipment apilal work-in-progress Dither initiagible assets cinancial assets cinancial assets con-current tax assets (net) bither non current assets con-current assets that assets that assets initiancial assets cinancial assets cinancial assets cinancial assets cinancial assets		3,282.07 121.63 38.97 833.81 2933.27	3,390.62 76.20 12.33 739.46 434.93 549.62 549.63 549.63	
ž Pů	rrent assets Toperty, plant and equipment Japital work-in-progress Jubre Intangible assets Inancial assets Loans L		3,282.07 131.63 38.97 833.81 833.81	3,390.62 76.20 12.33 739.46 739.45 549.62 549.63 549.63 549.63	
r o	Tapticuty prant and equipment Taptical assets Ther Intanglie assets Transfal assets frankal assets for-current assets for - current assets for - current assets for - current assets fransets trassets	2 014 BG	12163 12163 38.97 833.81 293.27	735.02 735.02 739.46 739.46 434.93 549.62 549.62 543.59	
ڻ <sup>ي</sup>	inancial assets Loans Loans don-current tax assets (net) don-current assets (net) Dher nor urrent assets Jon - Current Assets Tassets Tventories Tventories	342.76	833.81 293.27	739.46 739.46 549.62 549.63 5,243.59	
p d	Lours tor-current tax assets (net) eferred tax assets (net) Dine ron current assets Jon - Current Assets tassets remotical assets inancial assets	10.040	293.27	5,240 434,93 549,62 549,62 5,243,59	
Ŭ <sup>1</sup>	eferred tax assets (ret) Diter non current assets ta - current Assets ta assets rventorias	1,018.14	10 000	549.62 40.43 5,243.59	
0 4	lon - Current Assets it assets inancial assets	656.97 54.36	660.07 9.84	5,243.59	
บี	rt assets rventories inancial assets	5,797.44	5,239.66		
	inancial assets	733.55	612.54	986.60	
Ξ	(i) Trade receivables	707.10	662.80	758.65	
E	(ii) Cash and cash equivalents (iii) Bank balances other than (ii) above	182.85 55.86	228.38 56.51	186.33 55.90	
	(iv) Loans (v) Other Financial Assets	205.07	6.74 100.35	55.50 97.89	
(c) Oth Total Cu	(c) Other current assets	415.62 2.300.05	327.62	354.06	
Total Ac		00 200 0	03 100 1	C3 0CL L	
		0,031.43	00.402,1	70.0011	
B EQUITY	EQUITY AND LIABILITIES				
8	urty 1. (a) Other Equity	470.00	470.00	470.00	
Total Equity	iquity	3,505.91	2,940.31	2,278.38	
2 Liabilities 2 Non-curre (a) Final - Bor (b) Prov	Liabilities Non-current liabilities (a) Francial Liabilities - Borrowings (b) Provisions	533.54 100.30	1,291.22 84.56	1,754.24 30.12	
(c) OII Total No	(c) Other non-current labilities Total Non - Current Liabilities	875.53	1/3.00	1,896.86	EVO
3 Current (a) Fin (b) (b) (b) (c) (c) (c) (c) (c) (c) (c) (c) (c) (c	Current liabilities (a) Financial Liabilities () Borrowings () Trade Posobles	500.40 1.754.35	323.11 1 383 75	628.70 1.825.98	CHENNAL STIC
(iii)	(iii) Other financial liabilities	1,212.62 155.56	777.85 170.42	818.47 226.11	
Total Cu	Total Current Liabilities	3,716.05	2,744.86	3,563.28	*
Total Eq	Total Equity and Liabilities (1+2+3)	8,097.49	7,234.60	7,738.52	)



	Dr. Agarwal's Eye Hospital Limited Dr. Agarwal's Eye Hospital Limited CIN : L85110TN199APLC027366 Regd Office: 3rd Floor, Buhari Towers, No.4, Moores Road, Off Greams Road, Chennai - 600 006 Phone No. 91-44-39916669 Website : www.dragarwal.com E-mail : investor@dragarwal.com	Dr. Agarwal's Eye Hospital Limited CIN : L.B51101N1994PLC027366 Towers, No.4, Moores Road, Off Gi lebsite : www.dragarwal.com E-m.	ted 6 6 Greams Road, Chennai -mail : Investor@dragarv	- 600 006 val.com	
Notes: 1	<ol> <li>The above audited financial results have been reviewed by the Audit Committee, approved and taken on record by the Board of Directors in their Meeting held on 28 May 2018.</li> </ol>	ord by the Board of Direc	tors in their Meeting held on 28	May 2018.	(Amount in Rs. Lakhs)
	2 The Company has adopted Indian Accounting Standard ("Ind AS") from 1 April 2017 with a transition date from 1 April 2016 and accordingly, these financial results have been prepared in accordance with Ind AS prescribed under Section 133 of the Companies Act, 2017 read with the relevant trates issued three under and the other accounting principles generally accepted in India. The reconditation between financial results for the quarter and year ended 31 March 2017 and Equity for the year ended 31 March 2017 and 1 April 2016, as previously reported (referred to as 'Indian GAAP') and Ind AS is as under: the year ended 31 March 2017 and 1 April 2016, as previously reported to as 'Indian GAAP') and Ind AS is as under: (a) Statement of reconciliation of net profit after tax under Indian GAAP) and Ind AAS is as under: (b) Statement of reconciliation of net profit after tax under Indian GAAP) for the previous periods:	m 1 April 2016 and acc s generally accepted in I d AS is as under: ler Indian GAAP (IGAAP	rdingly, these financial results India.The reconciliation between 1 for the previous periods: (Amount in Rs. Lake)	have been prepared in a n financial results for th	eccordance with Ind AS prescribed under Section 133 of e quarter and year ended 31 March 2017 and Equity for
	Particulars (Rea	Quarter Ended 31 March 2017 (Refer Note 3 below)	Year Ended 31 March 2017 (Audited)		
	Net profit after tax under Previous GAAP	312.26	657.21		
	Actuarial Loss on employee defined benefit funds recognised in Other Comprehensive Income Fair value adjustments - Deposits Domotised cost adjustments - Financial Assets	45.04 14.90 (13.76)	40.75 52.30 (50.73)		
	Provision for protomyser at anticed uses used on Lineave interest nate Provision for Stepeted Credit Loss on Financial Assets Impact of Deferred Tax in respect of the above Adjustments Net profit for the period under Ind AS	(1.39) 2.85 (16.42) 343.28	(40.54) (40.54) 733.83		
	Other Comprehensive Loss (net of tax) Total Comprehensive Income under Ind AS	316.55	(26.65) 707.18		
	(b) Statement of reconciliation of Equity under Ind AS and Equity reported under Indian GAAP (JGAAP) as at:	) as at:	(Amount in Rs. Lakhs)		
	Particulars	As at 31 March 2017 (Audited)	As at 01 April 2016 (Audited)		
	Total Equity as reported under Previous GAAP	2,999.32	2,342.11		
	Reversal of Proposed Dividend and Dividend Distribution Tax Fair value adjustments – Deposits Amortised cost adjustments - Financial Assets	52.30 (93.12)	45.25		
	Recognition of borrowings at amorized cast based on Effective Interest Rate Provision for Expected Cast Loss on Financial Assets Deferred tax on Ind AS adjustments	17.55 (66.97) 31.23	24.11 (148.37) 57.67		
	Total Equity as reported under Ind AS	2,940.31	2,278.38		
	3 The figures for the quarters ended 31 March 2018 and 31 March 2017 are the balancing figures between the audited figures for the years ended 31 March 2018 and 31 March 2017 and the unaudited year to date figures for the nine months ended 31 December 2017 and 51 December 2016, respectively, which were subject to limited review by the Statutory Auditors.	re audited figures for the Statutory Auditors.	years ended 31 March 2018 4	and 31 March 2017 and	t the unaudited year to date figures for the nine months
	4 The Company operates in a single segment i.e. "Eye Care related sales and services" and hence, does not have any additional disclosures to be made under Ind AS 108 - Operating Segments	lave any additional disclo	sures to be made under Ind AS	3 108 - Operating Segm	ents.
	5 The Board of Directors at its meeting held on 28 May 2018 have recommended a final dividend of Rs. 1.20 per equity share subject to the approval of the shareholders.	er equity share subject to	the approval of the sharehold	,ca	
				By order of	By order of the Board
place	Place : Crhnnai			Dr. Amar Chairman & Ma	Dr. Amar Agarwal Chairman & Managing Director
Date	Date : 28 May 2018			DIN No. 0	N.
					)*



# Deloitte Haskins & Sells

Chartered Accountants ASV N Ramana Tower 52, Venkatnarayana Road T. Nagar Chennai - 600 017 Tamil Nadu, India

Tel: +91 44 6688 5000 Fax: +91 44 6688 5050

## INDEPENDENT AUDITOR'S REPORT TO THE BOARD OF DIRECTORS OF DR. AGARWAL'S EYE HOSPITAL LIMITED

- We have audited the accompanying Statement of Financial Results of DR. AGARWAL'S EYE HOSPITAL LIMITED ("the Company") for the year ended 31 March 2018 ("the Statement"), being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as modified by Circular No. CIR/CFD/FAC/62/2016 dated 5 July 2016.
- 2. This Statement, which is the responsibility of the Company's Management and approved by the Board of Directors, has been compiled from the related Ind AS financial statements which has been prepared in accordance with the Indian Accounting Standards prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder ('Ind AS') and other accounting principles generally accepted in India. Our responsibility is to express an opinion on the Statement based on our audit of such financial statements.
- 3. We conducted our audit in accordance with the Standards on Auditing issued by the Institute of Chartered Accountants of India. Those Standards require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether the Statement is free from material misstatement.

An audit involves performing procedures to obtain audit evidence about the amounts and the disclosures in the Statement. The procedures selected depend on the auditor's judgment, including the assessment of the risks of material misstatement of the Statement, whether due to fraud or error. In making those risk assessments, the auditor considers internal control relevant to the Company's preparation and fair presentation of the Statement in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control. An audit also includes evaluating the appropriateness of the accounting policies used and the reasonableness of the accounting estimates made by the Management, as well as evaluating the overall presentation of the Statement.

We believe that the audit evidence obtained by us is sufficient and appropriate to provide a basis for our audit opinion.

- 4. In our opinion and to the best of our information and according to the explanations given to us, the Statement:
  - (i) is presented in accordance with the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as modified by Circular No. CIR/CFD/FAC/62/2016 dated 5 July 2016; and
  - (ii) gives a true and fair view in conformity with the aforesaid Indian Accounting Standards and other accounting principles generally accepted in India of the net profit and Total comprehensive income and other financial information of the Company for the year ended 31 March 2018.



# Deloitte Haskins & Sells

5. The Statement includes the results for the Quarter ended 31 March 2018 being the balancing figure between audited figures in respect of the full financial year and the published year to date figures up to the third quarter of the current financial year, which were subject to limited review by us.

For **DELOITTE HASKINS & SELLS** Chartered Accountants (Firm's Registration No. 008072S)

V Balaji Partner

(Membership No. 203685)



CHENNAI, 28 May 2018 VB/JT/RB/2018/15



May 28, 2018

Dept. of Corporate Services Corporate Relationship Department BSE Ltd PhirozeJeejeebhai Towers, Dalal Street, Mumbai – 400001

Dear Sir,

Sub: Declaration in respect of Statutory Auditors' Report with Unmodified opinion – reg.
 Ref: 1) Regulation 33 of the SEBI (LODR) Regulation, 2015
 2) Scrip Code: 526783

We hereby declare that the Statutory Auditors of the Company, M/s. Deloitte Haskins & Sells (Firm Registration Number 0080725), Chartered Accountants, Chennai, have issued the Audit Report with Unmodified Opinion with respect to the Audited Financial Results for the Financial Year ended 31<sup>st</sup> March 2018.

Kindly take the above information on record.

Thanking you,

Yours truly,

S. LAKSHMI NARASIMHAN COMPANY SECRETARY & COMPLIANCE OFFICER DR. AGARWAL'S EYE HOSPITAL LTD



### **Registered** Office

3<sup>rd</sup> Floor, Buhari Towers, No.4, Moores Road, Off Greams Road, Near Asan Memorial School, Chennai - 600 006. Tel: 91-44-3991 6600 Fax: 91-44-3991 6645 Corporate ID Number: L85110TN1994PLC027366 GST No. 33AAACD2373G1Z2 Email: dragarwal@vsnl.com | Website: www.dragarwal.com